pretickt

Is ZTS a good stock to buy?

Zoetis Inc. · end-of-day data as of Nov 13, 2026

Zoetis
ZTS · $34.06B
$83.82+1.0%
Nov 13, 2026 · close
$70$80$90SepOctNov9:3016:003 months +14.1%Nov 13 · close
▲ 7
  • PT$97.67 +16.5%
  • ConsensusBuy · 17
  • P/E vs own-11.2%
  • P/E vs sector-55.7%
  • FCF yield+6.7%
  • MAs3 of 4
  • Sector▲ +15.9%
Neutral
  • Earnings in90d
  • P/E14.3x
  • RSI59
  • Support-3.9%
  • Resistance+34.6%
  • Off 52w high-36.7%
  • Volume0.7x
  • Bollingerupper half
  • News0.00
  • Trendsideways
  • 52w range$69–$132
  • ATR+3.0%
  • Off ATH-66.4%
  • InsidersNone in 90d
▼ 1
  • MACD-0.05

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Zoetis a good stock to buy?

Zoetis is strong on 3 of the 5 questions about the business. The price is low: 14.3 times its earnings, below its 3-year median of 28.2 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand steady
  2. Advantage some edge
  3. Economics very profitable
  4. Execution delivers
  5. Fragility sturdy
  6. Price below its usual
DemandDo people want more of what it sells?steady

ZTS sales growth revenue growth

+5%a year, for the last 3 years

Zoetis' sales grew 5% a year for 3 years, to $9.47B in fiscal 2025.

ZTS analysts' forecast revenue estimates

-2%the sales they expect next fiscal year, on the last

Analysts expect Zoetis' sales to fall 2% to $9.27B in fiscal 2026 (10 analysts).

ZTS peers

pretickt analysis+1%its sales in 12 months, on a year before

Zoetis' sales grew 1% in the 12 months to Sep 30, 2026, slower than ResMed (+9%), Mettler-Toledo (+7%), Centene (+5%) and Viatris (+4%).

ZTS sales by business revenue by segment

68%of its sales from Horses

Horses brought Zoetis 68% of its sales in fiscal 2025; Cattle 16%.

Advantage moatIs it hard to copy?some edge

ZTS return on capital ROIC

pretickt analysis163%earned before tax on the money invested in it

Zoetis earned 163% before tax on the capital invested in it in the 12 months to Sep 30, 2026; ResMed 34%, Mettler-Toledo 21%, Centene 7% and Viatris 0%.

ZTS margin on each sale gross margin

71%left after making the product

Zoetis kept 71% of each sale after making the product in the 12 months to Sep 30, 2026; its peers' median is 47%.

EconomicsDoes it make good money?very profitable

ZTS margin after costs profit margin

37%of sales left after running the business

Zoetis' operating margin was 37% in the 12 months to Sep 30, 2026, against 36% in fiscal 2022.

ZTS cash generated free cash flow

$2.28Bcash left after investing, last 12 months

Zoetis generated $2.28B of free cash flow in the 12 months to Sep 30, 2026, about as much as its reported profit.

ZTS profit per share

+10%in its last fiscal year

Zoetis' earnings per share grew 10% in fiscal 2025, to $6.02.

ExecutionDoes it deliver what it promises?delivers

ZTS earnings vs estimates

7 of 8quarters above the analysts' estimate

Zoetis beat the analysts' profit estimate in 7 of its last 8 quarters, the latest on Nov 5, 2026.

ZTS insider selling

-$1.65Msold, net, by its executives in 12 months

Zoetis' executives and directors sold a net $1.65M of shares in the 12 months to Nov 13, 2026 ($2.54M sold, $886K bought).

ZTS number of employees

+5%more people in a year

Zoetis had 14,500 employees at the end of fiscal 2025, 5% more than a year before.

ZTS CEO pay

$17.21Mfor fiscal 2024, 74% of it in stock and options

Zoetis paid its CEO $17.21M for fiscal 2024, 74% of it in stock and options.

Fragility risksCould something break it?sturdy

ZTS financial health Altman Z-score

4.8Altman Z-score, safe above 3

Zoetis' Altman Z-score is 4.8 (Nov 13, 2026), above 3, where the safe zone starts.

ZTS quality checks Piotroski score

7 of 9checks passed

Zoetis passes 7 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on return on assets and the current ratio.

ZTS biggest customers

16%of sales from its biggest customer

One customer, unnamed in Zoetis' 10-K, made 16% of its sales in fiscal 2025.

Price valuationIs the price reasonable?below its usual

ZTS price vs profit P/E ratio

14.3×a year's earnings

Zoetis' P/E ratio is 14.3 (Nov 13, 2026), below its 3-year median of 28.2.

ZTS price vs peers

pretickt analysis14.3×a year's earnings, against its peers

Investors pay 14.3 times Zoetis' earnings (Nov 13, 2026), less than for Mettler-Toledo (37.7), Centene (24.4) or ResMed (21.9).

ZTS analysts' target price target

+17%to their average target

Analysts' average price target for Zoetis is $97.67, 17% above the Nov 13, 2026 close of $83.82.

ZTS analyst ratings, 90 days

pretickt analysis
  • Jefferiesdowngrade
0 up, 1 downratings raised and cut

In the 90 days to Nov 13, 2026, Jefferies downgraded Zoetis.

ZTS growth priced in fair value

pretickt analysis+3%a year, for ten years, to be worth the price

At $83.82 a share, Zoetis' free cash flow must grow about 3% a year for ten years to be worth the price (Nov 13, 2026).

What is Zoetis' P/E ratio?

Zoetis' P/E ratio is 14.3 (Nov 13, 2026), below its 3-year median of 28.2. Investors pay 14.3 times Zoetis' earnings (Nov 13, 2026), less than for Mettler-Toledo (37.7), Centene (24.4) or ResMed (21.9).

Is Zoetis profitable?

Zoetis' operating margin was 37% in the 12 months to Sep 30, 2026, against 36% in fiscal 2022. Zoetis generated $2.28B of free cash flow in the 12 months to Sep 30, 2026, about as much as its reported profit.

Are insiders selling Zoetis stock?

Zoetis' executives and directors sold a net $1.65M of shares in the 12 months to Nov 13, 2026 ($2.54M sold, $886K bought).

How does Zoetis make money?

Horses brought Zoetis 68% of its sales in fiscal 2025; Cattle 16%.

How many employees does Zoetis have?

Zoetis had 14,500 employees at the end of fiscal 2025, 5% more than a year before.

Who are Zoetis' biggest customers?

One customer, unnamed in Zoetis' 10-K, made 16% of its sales in fiscal 2025.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.